Immunophenotyping of MSC by flow cytometry was reported elsewhere[14 (
link)]. Unless stated otherwise, fluorescence-conjugated monoclonal antibodies from Beckman Coulter were used. They were
IgG1-FITC,
IgG1-PE,
HLA-DR-FITC,
CD45-FITC,
CD3-FITC,
CD19-PE,
CD16-FITC,
CD33-FITC,
CD38-FITC,
CD34-PE,
CD133-PE (Miltenyi Biotec GmbH, Germany),
CD29-PE,
CD44-FITC, CD73-FITC,
CD90-PE,
CD105-PE (Serotec, United Kingdom) and CD166-PE were used. At least 10000 events were acquired and signals were analysed by using the Coulter Epic XL MCL flow cytometer (Coulter, Miami, FL, United States).
Procedural details of immunofluorescence staining were described previously[15 (
link)]. IgM anti-stage-specific embryonic antigen-4 (SSEA-4, 1:100; Santa Cruz Biotechnology, Santa Cruz, CA, United States), IgG
2b anti-octamer-binding transcription factor-4 (Oct-4; 1:100, Santa Cruz Biotechnology), IgG
1 anti-Nestin (1:400; BD Biosciences, San Francisco, CA, United States) were employed.
Cell viability was evaluated by using trypan blue dye exclusion test. Sterility check against microbial contamination was conducted at each MSC passage.
Tsang K.S., Ng C.P., Zhu X.L., Wong G.K., Lu G., Ahuja A.T., Wong K.S., Ng H.K, & Poon W.S. (2017). Phase I/II randomized controlled trial of autologous bone marrow-derived mesenchymal stem cell therapy for chronic stroke. World Journal of Stem Cells, 9(8), 133-143.